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S U M M A R Y
Background: Dengue is a notiﬁable infectious disease in many countries, but under-reporting of cases to
National Epidemiological Surveillance Systems (NESSs) conceals the true extent of the disease burden.
The incidence of dengue identiﬁed in a cohort study was compared with those reported to NESSs.
Methods: A randomized, placebo-controlled study was undertaken in Brazil, Colombia, Honduras,
Mexico, and Puerto Rico to assess the efﬁcacy of a tetravalent dengue vaccine (CYD-TDV) in children aged
9–16 years. The incidence of dengue in the placebo group was compared with that reported to NESSs in a
similar age group (10–19 years) from June 2011 to April 2014.
Results: Three thousand six hundred and ﬁfteen suspected dengue cases were identiﬁed in the study
over 13 527 person-years of observation. The overall incidence of conﬁrmed dengue was 2.9 per
100 person-years (range 1.5 to 4.1 per 100 person-years). In the NESSs combined, over 3.2 million
suspected dengue cases were reported during the same period, corresponding to over 1 billion person-
years of observation. The incidence of conﬁrmed dengue reported by the NESSs in the same locality
where the study took place was 0.286 per 100 person-years across Brazil, Colombia, and Mexico (range
0.180 to 0.734 per 100 person-years). The incidence of conﬁrmed dengue was 10.0-fold higher in the
study than that reported to NESSs in the same localities (range 3.5- to 19.4-fold higher).
Conclusions: There is a substantial under-reporting of dengue in the NESSs. Understanding the level of
under-reporting would allow more accurate estimates of the dengue burden in Latin America.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Dengue is an endemic disease caused by an arbovirus of the
family Flaviviridae, transmitted to humans through the bite of
female mosquitoes of the Aedes genus (mainly Aedes aegypti)
infected by one of four dengue virus serotypes, DENV-1–4. Clinical
manifestations range from a non-speciﬁc febrile illness to a
potentially more severe or life-threatening disease, such as dengue
haemorrhagic fever (DHF) or dengue shock syndrome (DSS), and in
some cases may lead to death.1
Routine dengue surveillance in endemic countries is essential
for monitoring disease trends and detecting outbreaks, thus* Corresponding author. Tel.: +52 5554 8448 41.
E-mail address: elsa.sarti@sanoﬁpasteur.com (E. Sarti).
http://dx.doi.org/10.1016/j.ijid.2016.01.015
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).allowing decision-makers and health systems to have timely
information on which to act whenever needed. Previous studies
have revealed considerable under-reporting in national surveil-
lance systems in endemic regions, limiting their ability to quantify
the incidence or provide reliable estimates of future trends.2,3
Indeed, to provide more accurate estimates of dengue disease
burden and costs, analysts use country-speciﬁc expansion factors
derived from cohort study estimates to account for the under-
reporting of cases from national surveillance data.4–7 However,
these estimates remain mostly speculative and are based on small
populations. In a systematic review of dengue surveillance in
endemic countries, Runge-Ranzinger et al. identiﬁed the need for
further research to help identify strategies to strengthen surveil-
lance systems and to allow the identiﬁcation of appropriate
thresholds of excess reporting.2ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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and they circulate simultaneously in several countries.8 Large
epidemics have recently occurred in the Caribbean, Brazil,
Colombia, Ecuador, Mexico, and Venezuela.9 Despite concerted
dengue control efforts, the disease has continued to increase
substantially in Latin America.10 The number of suspected dengue
cases reported by the National Epidemiological Surveillance
Systems (NESSs) in the region increased from 652 212 in 200011
to 2 386 836 in 2013,12 and dengue-related registered deaths
increased from 9213 to 1318 in the same period.12
A phase III, randomized, placebo-controlled study (CYD15) was
undertaken to evaluate the safety and efﬁcacy of a recombinant live-
attenuated tetravalent dengue vaccine (CYD-TVD) in healthy
children aged 9–16 years (n = 20 869) over 25 months in ﬁve Latin
American countries (Brazil, Colombia, Honduras, Mexico, and Puerto
Rico).14 The longitudinal follow-up of placebo recipients (n = 6939)
provided a unique opportunity to examine the background
incidence of dengue in this well-deﬁned cohort. The incidence
rates observed in the placebo group of the CYD15 study cohort were
compared with data reported by the NESSs for a comparable age
group and in the same geographic areas (locality/sites).
2. Methods
2.1. Data sources
2.1.1. CYD15 study data
The Latin American CYD-TDV (CYD15) study has been described
previously.14 Healthy children aged 916 years were recruited at
22 centres in Colombia (nine centres), Brazil (ﬁve centres), Mexico
(ﬁve centres), Puerto Rico (two centres), and Honduras (one centre)
between June 2011 and April 2014. Active dengue surveillance
started on the day of the ﬁrst vaccination or receipt of placebo
control and continued for 25 months for each participant.
Participants were followed closely for acute febrile illness
(temperature 38 8C on two or more consecutive days), and those
who presented with fever were screened for signs and symptoms
of dengue. Acute and convalescent blood samples were obtained
and assessed using a quantitative reverse-transcriptase PCR (RT-
PCR) assay for dengue ampliﬁed genomic sequences, and an ELISA
for dengue non-structural protein 1 (NS1) antigen, in accordance
with the guidelines of the World Health Organization (WHO).15,16
Virological conﬁrmation of suspected dengue was undertaken
under blinded conditions at the sponsor’s global clinical immu-
nology laboratories (at the Centre for Vaccine Development of
Mahidol University in Bangkok, Thailand) and at Focus Diagnostics
(California, USA), permitting highly rigorous and comparable
results across all study sites to be obtained. The illness episode was
classiﬁed as virologically conﬁrmed dengue if any of the tests was
positive.
This article focuses on data obtained in the placebo group
through to April 2014. All acute febrile episodes, conﬁrmed
dengue, and DHF or severe dengue (SD) cases were summarized by
country for the entire placebo cohort over the whole follow-up
period. Incidence rates for conﬁrmed dengue and DHF/SD cases
were obtained by dividing total numbers of these events by the
person-years of follow-up, as reported elsewhere.17 The 95%
conﬁdence intervals (CI) for incidence rates and proportions were
computed with the exact binomial distribution for percentages
(Clopper–Pearson method).18
2.1.2. Census data
The population census data for the country were obtained from
the Instituto Brasileiro de Geograﬁa e Estatı´stica for Brazil,19,20
Departamento Administrativo Nacional de Estadı´stica for
Colombia,21 the National Institute of Statistics for Honduras,22Consejo Nacional de Poblacio´n for Mexico,23 and the US Census
Bureau for Puerto Rico.24 Population data were disaggregated into
groups by age and regional jurisdiction (state and local level). The
cumulative age-speciﬁc dengue cases for the follow-up study
period (2011–2014) in the municipalities/sites where the study
was undertaken in each country were used in the calculation of the
country-speciﬁc dengue incidence rates.
2.1.3. NESS description
The NESS characteristics for the participating countries, as well
as the clinical and laboratory criteria used for dengue notiﬁcation,
are summarized in the Supplementary Material (Appendix S1,
Table S1). Physicians and other healthcare providers are required
to report suspected cases meeting the WHO criteria. There are
currently two WHO case deﬁnitions used: the 1997 classiﬁcation
(dengue fever (DF), dengue haemorrhagic fever (DHF), and dengue
shock syndrome (DSS)),1 and the 2009 case classiﬁcation (dengue
without warning signs (D), dengue with warning signs (DWS), and
severe dengue (SD)).15 Each country has since adapted these
deﬁnitions in line with their national experience; the country-
speciﬁc case deﬁnitions for suspected dengue are summarized in
the Supplementary Material (Table S2).
Each country has speciﬁc national guidelines/algorithms regard-
ing the assays/tests to undertake and the proportion of suspected
cases to assess, depending on whether the cases are identiﬁed during
endemic or epidemic situations, as well as when they can declare
suspected cases as conﬁrmed by simple epidemiological association
during epidemics when the virus is known to be circulating
(Supplementary Material, Tables S1 and S2). Dengue diagnosis
based solely on clinical symptoms is unreliable and the need for
laboratory conﬁrmation is emphasized by the WHO.1 It is
recommended that blood samples for suspected cases be collected
within 5 days of fever onset (acute sample) and during convales-
cence (convalescent sample) about 10 days after the acute sample. A
suspected case is considered conﬁrmed with one of the following:
isolation of the dengue virus, detection of dengue virus genomic
sequences or antigens, or if there is a 4-fold or greater increase in
dengue-speciﬁc IgG or IgM titres in paired serum.1,15
2.1.4. NESS data
Data on conﬁrmed and suspected dengue cases were collected
from the NESSs from June 2011 to April 2014, corresponding to the
9-month enrolment period plus 25 months follow-up for each
participant in the CYD15 study. The number of suspected and
conﬁrmed dengue cases, DHF/SD cases, and deaths reported were
summarized by age, time of occurrence, and by regional level
(country, state/department, municipalities/sites). These data were
used to calculate incidence rates of suspected and conﬁrmed
dengue cases and DHF/SD cases corresponding to each participat-
ing city/municipality, state, and country. Incidence rates were
obtained by dividing total numbers of cases with the person-years
of follow-up. The 95% CI for incidence rates and proportions were
calculated using the binomial distribution for percentages.25 The
case-fatality rate (CFR) was estimated based on the ratio of
dengue-related deaths to total conﬁrmed DHF/SD cases, and to
suspected cases.
The NESS dengue reports from Brazil, Colombia, and Mexico
(but not from Honduras and Puerto Rico) were usually consolidat-
ed into 5-year age groups (with the exception of children <1 year
of age and those aged >65 years). In order to be close to the age
groups recruited in the CYD15 study (age 9–16 years) and
considering that after 12 months of recruitment this population
would have aged to 10–17 years and after 24 months to 11–18
years, it was decided to aggregate data from the NESSs in these
three countries for two age groups: 10–14 and 15–19 years. Age-
stratiﬁed data were not available for Honduras and Puerto Rico.
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Incidence rates from the placebo group of the CYD15 study
were compared with their respective age-speciﬁc (10–19 years age
group) incidence rates reported by the NESSs by country, as well as
by state and by municipality/site level. Analyses of DHF (severe
dengue) cases from the NESS Honduras were based on clinical
features only because laboratory conﬁrmation of severe dengue is
not undertaken.
2.3. Role of funding source
Sanoﬁ Pasteur had the opportunity to review and comment on
this manuscript.
3. Results
3.1. CYD15 study data
In the CYD15 study, 6939 children and adolescents were
enrolled at a mean age of 12.5  2.1 years. During 13 527 person-
years of follow-up, there were 3613 suspected dengue cases, of which
389 episodes were virologically conﬁrmed to be dengue and
10 episodes were conﬁrmed to be DHF, providing an overall incidence
rate of 2.9 per 100 and 73.9 per 100 000, respectively (Table 1).
Honduras had the highest incidence rate for febrile episodes
(51.08 per 100 person-years) and virologically conﬁrmed dengue
cases (4.10 per 100 person-years). There were no virologically
conﬁrmed DHF/SD cases reported in Brazil or Mexico, and the
virologically conﬁrmed DHF/SD cases as a percentage of total
virologically conﬁrmed dengue cases across the other three countries
ranged from 2.7% to 7.7%.
3.2. NESS data
Across the ﬁve countries, there were over 3.2 million suspected
dengue cases reported to the NESSs across all age groups during the
period June 2011 to April 2014, from over 1 billion person-years of
observation. The numbers of suspected and conﬁrmed dengue
cases and DHF/SD cases reported, as well as the corresponding
incidence rates, are summarized for each country in the
Supplementary Material (Tables S3–S7). The incidence rate of
suspected dengue ranged from 0.1 per 100 person-years in
Colombia to 0.45 per 100 person-years in Brazil and Puerto Rico;
the corresponding incidence rate of conﬁrmed dengue ranged from
0.004 per 100 person-years in Honduras to 0.31 per 100 person-
years in Brazil (Table 2). Although Brazil had the highest incidence
rates for both suspected and conﬁrmed dengue cases, it had the
lowest incidence rates for conﬁrmed DHF/SD (0.59 per 100 000 per-
son-years). The overall incidence rate for conﬁrmed DHF/SD wasTable 1
Data from the CYD15 study cohort (aged 9–16 years) for the period June 2011 to Apri
Brazil Colo
Number of participants, N 1174 324
Population observation, person-years 2290 631
Number of febrile episodes, n 552 148
Febrile episodes, IR per 100 participants 24.10 2
Number of conﬁrmed dengue episodes, n 81 16
Conﬁrmed dengue episodes, IR per 100 person-years 3.50 
Number of conﬁrmed DHF/SD episodes, n 0 
Proportion of conﬁrmed DHF/SD episodes, % 0.00 
IR of conﬁrmed DHF/SD episodes per 100 000 person-years 0.00 11
IR, incidence rate; DHF, dengue haemorrhagic fever; SD, severe dengue.
a Numbers shown in parentheses are for the adjusted denominator (i.e., without Ho
Epidemiological Surveillance System, to allow for the necessary comparative analyses;4.89 per 100 000 person-years across all countries excluding
Honduras. Honduras had the highest incidence rate for DHF
(35.24 per 100 000 person-years), but this ﬁgure is based on
clinical features without laboratory conﬁrmation.
3.3. Comparison between the CYD15 study cohort and NESS data
There were consistently more cases identiﬁed in the CYD15
study than were reported via the NESSs in a similar age-stratiﬁed
cohort at all levels in the three countries (age-stratiﬁed data were
not available for Honduras or Puerto Rico) (Table 3). The incidence
rates for conﬁrmed dengue cases were on average 25.1-fold higher
in the CYD15 study than reported in the NESSs at the national level
across the three countries, and 12.0- and 10.0-fold higher at the
state and local levels, respectively. The greatest disparity was
found for Brazil with 16.9- and 19.4-fold higher conﬁrmed dengue
cases in the CYD15 study than at the state and local levels, and the
lowest disparity was found for Colombia at 5.8- and 3.5-fold
higher, respectively.
In a crude comparison, the incidence rates for conﬁrmed
dengue cases were 978- and 9.4-fold higher in the CYD15 study
than reported across all age groups in the NESSs for Honduras and
Puerto Rico, respectively.
4. Discussion
This analysis is one of the few studies to compare active
surveillance with passive surveillance in different countries. There
was a much higher incidence of conﬁrmed dengue identiﬁed
during active surveillance in the cohort study than reported to the
NESSs, even when considering comparable data at the state level
and at the municipality/site level. The expansion factors calculated
(Table 3), indicating the level of under-reporting, varied consider-
ably by country. However, these expansion factors should be
interpreted with caution, as the study locations and age groups
assessed in the CYD15 study were not selected randomly and as
such, may not necessarily be representative of their respective
countries overall.
It is generally recognized that there is a tendency for passive
NESSs to under-report dengue cases, particularly for less severe
non-hospitalized cases.2 The variability in under-reporting makes
it difﬁcult to compare the incidence rates both within and between
countries. There are a number of factors that contribute to under-
reporting in passive NESSs. Many people or parents do not usually
seek treatment for a mild febrile illness (including mild dengue)
unless they have cause for concern. Under-reporting may also
occur to a greater extent among the older age groups, where febrile
illnesses may easily be dismissed. There is also the possibility of
misdiagnosis, especially with less severe dengue, with other
infectious diseases confounding the diagnosis. In addition,l 2014
mbia Honduras Mexico Puerto Rico Overalla
5 931 1149 440 6939
3 1799 2280 845 13 527 (11 728)
6 919 473 185 3615
3.54 51.08 20.75 21.89 2672
5 73 57 13 389
2.60 4.10 2.50 1.50 2.87
7 2 0 1 10 (8)
4.24 2.74 0.00 7.69 2.57
0.88 111.17 0.00 118.34 73.93 (68.21)
nduras because it does not report laboratory-conﬁrmed DHF cases in the National
 the diagnosis of DHF is based on clinical features only).
Table 2
Summary of national dengue cases (all age groups) reported to National Epidemiological Surveillance Systems for the period June 2011 to April 2014
Brazil Colombia Honduras Mexico Puerto Rico Overalla
Population observation, person-years 564 937 700 132 453 602 23 927 087b 332 795 595 10 351 002 1 064 464 986 (1 040 537 899)
Number of suspected dengue cases, n 2 522 527 126 959 63 873 470 692 47 001 3 231 052
Suspected cases, IR per 100 population 0.45 0.10 0.27 0.14 0.45 0.30
Number of conﬁrmed dengue cases, n 1 750 307 114 225 831 134 931 16 489 2 016 783
Conﬁrmed cases, IR per 100 population 0.310 0.086 0.004 0.041 0.16 0.189
Number of conﬁrmed DHF/SD cases, n 3320 4054 8432b 43 355 114 59 275 (50 843)
DHF/SD from conﬁrmed cases, % 0.19 3.55 0.00 32.13 0.69 2.94
DHF/SD from suspected cases, % 0.13 3.19 13.20b 9.21 0.24 1.83
Number of deaths, n 1328 256 35 369 22 2010
CFR (deaths/conﬁrmed DHF/SD cases) 40.00 6.31 0.42b 0.85 19.30 3.39
CFR (deaths/No. suspected cases) 0.05 0.20 0.05 0.08 0.00 0.06
IR conﬁrmed DHF/SD (DHF/SD/
population)  100 000
0.59 3.06 35.24b 13.03 1.10 5.57 (4.89)
IR, incidence rate (by 100 population); DHF, dengue haemorrhagic fever; SD, severe dengue; CFR, case-fatality rate.
a Numbers shown in parentheses are for the adjusted denominator (i.e., without Honduras because it does not report laboratory-conﬁrmed DHF cases in the National
Epidemiological Surveillance System, to allow for the necessary comparative analyses; the diagnosis of DHF is based on clinical features only).
b Due to a lack of data for conﬁrmed cases for 2011. Only years with complete data were taken into account. Severe dengue cases are not laboratory-conﬁrmed in Honduras;
the number of DHF cases reported here for Honduras represents suspected DHF cases.
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assessed, there is usually no practical way of ensuring compliance
with surveillance requirements. Other factors that may contribute
to under-reporting include limited laboratory capabilities or
infrastructure, as well as difﬁculties (or inconsistencies) in
applying the WHO dengue case deﬁnition. Under-reporting rates
may also differ depending on the epidemiological scenario—the
occurrence of outbreaks with increased disease awareness among
the population may reduce the rate of under-reporting,26,27 but
conversely may lead to over-reporting.28
The overall level of under-reporting for conﬁrmed dengue cases
(Brazil, Colombia, and Mexico) ranged from 10.0- to 25.1-fold in
this study, depending on whether the comparison was with the
local, state, or national level. These observations appear consistent
with those reported in another study comparing paediatric (age 2–
12 years) cohort-based data with NESS data in Nicaragua, in which
the expansion factor indicated the level of under-reporting to be
14–28-fold for conﬁrmed cases reported by the NESS.4 An earlier
analysis undertaken for Puerto Rico based on available data and on
expert opinion suggested that 10- and 27-fold more cases occur in
paediatric and adult populations, respectively, than are reported.5
Empirical estimates from several countries in Latin America
suggest under-reporting of 1.4–3.4-fold for hospitalized and fatal
cases, and of 2.1–28-fold for ambulatory cases.6 The level of under-
reporting estimated at the local level in Brazil (19.4-fold),
Colombia (3.5-fold), and Mexico (8.4-fold) in the present study
may be considered the closest to the real-life situation in these
countries.Table 3
Comparison between the CYD15 study cohort (aged 9–18 years) and National Epidemi
2011 to April 2014a
IR conﬁrmed cases per 100 (95% CI) 
CYD15 study
(control arm)
NESS(National) NESS(States) NE
Brazil 3.5 (2.8–4.4) 0.131 (0.1312–0.1314) 0.207 (0.2069–0.2074) 0.1
Colombia 2.6 (2.2–3.0) 0.204 (0.2042–0.2045) 0.445 (0.4450–0.4464) 0.7
Mexico 2.5 (1.9–3.2) 0.055 (0.0554–0.0556) 0.197 (0.1973–0.1980) 0.2
Overall 2.9 (2.6–3.2) 0.11 (0.1143–0.1145) 0.239 (0.2388–0.2392) 0.2
IR, incidence rate; CI, conﬁdence interval; NESS, National Epidemiological Surveillance
a Brazil and Mexico only include laboratory-conﬁrmed cases. Conﬁrmed cases in Colom
association and clinical ﬁndings). ‘National’ includes all information from the whole cou
sites’ includes the same localities (municipalities/sites) where the CYD15 study was peThe difference in dengue incidence rates reported in the NESSs
relative to the CYD15 study appeared to decrease progressively
from the national level through to the state and municipality/site
levels. The sites/regions selected for the study were based, in part,
on their capacity to undertake research and on the availability of
health staff to perform the ﬁeldwork in a timely manner, which
may indirectly reﬂect the efﬁciency or capability/infrastructure of
the healthcare system in the local area to report cases to the NESS.
In addition, the CYD15 study was a major, well-publicized study,
and it is possible that physicians and other healthcare providers in
the area where it was conducted may have been more aware or
reminded of the need to report suspected cases for laboratory
conﬁrmation. Alternatively, as the sites in the CYD15 study were
selected with the knowledge that they had a high dengue burden,29
the difference in incidence rates reported at the national level
compared with the study cohort may simply reﬂect the
geographical variability in the burden of dengue across these
countries.
The variation in the incidence rates of cases reported to the NESSs
may also reﬂect differences in healthcare systems or differences in
the case deﬁnition used. Although the Pan American Health
Organization (PAHO)—the regional ofﬁce for the Americas of the
WHO—provided standardized case deﬁnitions based on the
1997 WHO publication, later revised in 2009 according to disease
severity,1,15 each country has since adapted these deﬁnitions in line
with their national experience (Supplementary Material, Table S2).
This has led to some inconsistencies in case deﬁnitions between
countries. For instance, in Mexico, only laboratory-conﬁrmed casesological Surveillance System data (for those aged 10–19 years) for the period June
Ratio of
CYD15/
NESS(National)
Ratio of
CYD15/
NESS(State)
Ratio of
CYD15/
NESS(Local sites)
SS(Local sites)
80 (0.1797–0.1807) 26.7 (21.7–33.4) 16.9 (13.8–21.2) 19.4 (15.8–24.2)
34 (0.7320–0.7361) 12.7 (11.0–14.8) 5.8 (5.0–6.7) 3.5 (3.0–4.0)
97 (0.2957–0.2989) 45.5 (33.8–56.5) 12.6 (9.8–16.3) 8.4 (6.5–10.9)
86 (0.2857–0.2868) 25.1 (21.9–27.3) 12.0 (10.5–13.0) 10.0 (8.8–11.0)
 System.
bia are based on their own deﬁnition (laboratory conﬁrmed cases + epidemiological
ntry; ‘States’ includes only the states where the CYD15 study was performed; ‘Local
rformed.
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tion is also used as a criterion for conﬁrmation even in non-
epidemic circumstances. However, the Brazilian data can be
disaggregated into laboratory-conﬁrmed cases and laboratory-
conﬁrmed plus epidemiological association cases (ofﬁcial case
deﬁnition). Considering only laboratory-conﬁrmed cases in Brazil
at the site level, the CYD15 study data were 19.4-fold higher than
those reported to the NESS (Table 3), but were only 3.6-fold higher
than the respective NESS data when the ofﬁcial case deﬁnition was
used (ofﬁcial incidence rate was 0.98 per 100 at the site level)
(data not presented).
Data compared here were collected during a period that
included a dengue outbreak in Brazil in 2013. This was reﬂected by
the >2-fold higher incidence rate for conﬁrmed dengue cases
reported to the NESS during that year compared with the other
years of the study (Supplementary Material, Table S3). Similarly,
there was an outbreak in Honduras in the same year, reﬂected in
the data by a higher number of suspected dengue cases reported,
but which were not supported by the conﬁrmed incidence rate
(Supplementary Material, Table S5). As a consequence, the
cautious use of expansion factors obtained from different
epidemiological settings is recommended.
This study has a number of other limitations that also need to
be considered. The main limitation is that data obtained from a
cohort study undertaken at selected geographical settings in a
selected healthy paediatric population were compared with
national data, and as such are unlikely to be fully nationally
representative or even fully representative of the same age-
stratiﬁed paediatric population in the region where the study
was undertaken. In addition, age-stratiﬁed data were not
available for Honduras and Puerto Rico. Case reporting was
much lower in Honduras, and in particular, the low rate of
dengue conﬁrmation makes the data from that country difﬁcult
to interpret. This may, in part, be related to the lower sensitivity
of the laboratory techniques used in Honduras for conﬁrmation
of dengue, based on IgM and/or viral isolation, compared with
the WHO recommended combination of NS1 ELISA and/or RT-
PCR used by the other countries and in the CYD15 trial.15,30
Finally, the case deﬁnition for suspected dengue cases in the
study cohort was objectively deﬁned as acute febrile illness with
a temperature 38 8C for two or more consecutive days, and
differs from the symptomatic deﬁnition used in the NESSs
(Supplementary Material, Table S2).
In conclusion, there is an increasing need for better estimates of
the burden of dengue in order to better assess the impact of new
technologies for dengue control. This analysis shows that the rate
of reporting of conﬁrmed dengue varies considerably by country,
and that there is likely under-reporting of the number of cases
reported in the NESSs, which varies considerably by country. This
study should assist with more accurate estimations of the burden
of dengue determined from passive NESSs. Such estimates would
be useful when modelling dengue disease dynamics or in health
economics assessments.
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